Neurolixis announced the publication of a new patent on a series of serotonin 5-HT1A receptor agonists. The novel chemical entities (NCEs) are structural analogues of Neurolixis' lead compounds, NLX-112 and NLX-101 which are in clinical development for treatment of dyskinesia in Parkinson's disease and Rett syndrome, respectively. Patent WO/2017/220799 (priority date 24 June 2016) has co-inventors from Neurolixis and from Jagiellonian University, Krakow, as part of a continuing and fruitful drug discovery collaboration.

See the text of the patent on the World Intellectual Property website: WO/2017/220799

Newsletter

Veuillez activer le javascript sur cette page pour pouvoir valider le formulaire

Follow Neurolixis on: